New COPD Drug Cuts Flare-Ups 30% for 30,000 in England

People living with severe breathing problems finally have a treatment that addresses why their lungs keep failing them.

England's National Institute for Health and Care Excellence just approved dupilumab, a biologic drug that targets the underlying inflammation causing Chronic Obstructive Pulmonary Disease. Nearly 30,000 people whose COPD won't respond to maximum inhaler therapy can now access this home treatment.

The medication comes in pre-filled pens patients inject at home every two weeks. Clinical trials showed the drug reduced dangerous COPD flare-ups by 30%, while participants reported breathing more easily and showed measurable improvements in lung function.

For one patient who spoke at the evaluation meeting, biologic treatments "completely changed his life." Another described how COPD forces people to quit work entirely or slash their hours, devastating both patients and their families who watch them struggle for each breath.

COPD sends 130,000 people to emergency rooms across England every year. These flare-ups typically require steroid treatments that carry serious side effects, adding another layer of suffering to an already brutal disease.

The Ripple Effect

The benefits extend far beyond individual patients. If just half the eligible population receives dupilumab, England's health service could see 3,600 fewer COPD attacks and save an estimated £16.5 million annually.

Those savings mean fewer overcrowded emergency rooms and less reliance on steroids with their harsh side effects. Hospitals can redirect resources while patients avoid the revolving door of crisis care that defines severe COPD.

The drug targets adults with uncontrolled COPD who have raised blood eosinophil levels and experienced at least one severe flare-up or two moderate ones in the past year despite maximum inhaler therapy. About 1.2 million people in the UK live with a COPD diagnosis.

Helen Knight, NICE's director of medicines evaluation, called the approval "a significant milestone" offering genuine hope for better quality of life. Sarah Sleet of Asthma + Lung UK emphasized the need to ensure everyone who could benefit actually gets access to this life-changing treatment.

NHS England negotiated an innovative deal with French pharmaceutical company Sanofi to make the rollout possible, bringing cutting-edge care to patients while protecting taxpayer value.

For thousands who thought they'd exhausted every option, breathing easier just became possible again.